Cytokinetics, Inc.

Smithkline Beecham Corporation

Glaxosmithkline LLC

Glaxosmithkline Intellectual Property (no.2) Limited

Steven David Knight

Dashyant Dhanak

David John Morgans, Jr

Gustave Bergnes

Kenneth Allen Newlander

Andrew I McDonald

Joelle Lorraine Burgess

William Henry Miller

Nicholas D Adams

Bainian Feng

Xinrong Tian

Xiangping Qian

Neil W Johnson

Bing Yao

Stuart Paul Romeril

Han-Jie Zhou

Cynthia A Parrish

Sharad Kumar Verma

Christopher A Brook

Hong Jiang

Bradley Paul Morgan

Luke W Ashcraft

Kevin J Duffy

Meagan B Rouse

Jianchao Wang

Duke Fitch

Rosanna Tedesco

Jennifer Kuo Chen Huang

Stanley J Schmidt

Louis Lafrance

Pu-Ping Lu

Timothy Francis Gallagher

Michael Gerard Darcy

Louis Vincent Lafrance, Iii

Jian Jin

Juan I Luengo

Richard McCulloch Keenan

Jiri Kasparec

Mark James Schulz

Seth Wilson Grant

Dominic Suarez

Dai-Shi Su

Charles William Blackledge, Jr

James Brackley, Iii

Celine Duquenne

Louis V LaFrance, Iii

Carla A Donatelli

Gregory Lee Warren

Katherine L Widdowson

Martha A Sarpong

Anthony Sapienza

Lance Howard Ridgers

Mark Schulz

Ralph A Rivero

Pu Ping Lu

Christopher S Glaxosmithkline Brook

Dashyant Glaxosmithkline Dhanak

Kenneth A Glaxosmithkline Newlander

David J C Morgans

Lance Ridgers

Martha Sarpong

Louis Vincent Iii Lafrance

Louis V Lafrance Iii

Jr Charles William Blackledge

Iii Louis Vincent Lafrance

Kenneth C Mcnulty

Iii Alan Peterson Graves

Iii James A Brackley

This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers. 

Enhancer of zeste homolog 2 inhibitors

This invention relates to novel substituted benzamide according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers. 

Enhancer of Zeste Homolog 2 inhibitors

This invention relates to novel compounds according to Formula (III)(a) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), and to pharmaceutical compositions containing them. 

This invention relates to novel substituted benzamides according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers. 

Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.

Indoles

Herein are disclosed azaindazoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.

Azaindazoles

Herein are disclosed indazoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.

Indazoles

Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives.

Quinoline derivatives as PI3 kinase inhibitors

Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.

Imidazole-benzamide anti-cancer agents

Growing community of inventors

Collegeville, PA, United States of America

Steven David Knight